New combo aims to outsmart Platinum-Resistant ovarian cancer
NCT ID NCT07109414
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called NP-G2-044 (Prilukae) combined with standard chemotherapy (PLD) in people with ovarian cancer that no longer responds to platinum-based treatments. About 380 participants will receive either the combo or PLD alone to see if the combination improves tumor shrinkage and delays cancer growth. The trial also checks for side effects and aims to find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NP-G2-044 (Prilukae) and pegylated liposomal doxorubicin (PLD)
What this could lead to
If successful, this combination could offer a new treatment option that slows cancer growth and improves response rates for people with platinum-resistant ovarian cancer.
What could go wrong
This is an early-to-mid-stage trial, so the combination may not prove more effective than PLD alone. Side effects from the drugs could also limit tolerability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HonorHealth Cancer Care
Phoenix, Arizona, 85016, United States
-
Optimum Clinical Research Group, LLC
Albuquerque, New Mexico, 87109, United States
-
Trials365
Shreveport, Louisiana, 71133, United States
-
University Of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792-9988, United States
-
University of Pennsylvania Health System, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104-5127, United States
-
Utah Cancer Specialists
Salt Lake City, Utah, 84106, United States